PMID- 20869415 OWN - NLM STAT- MEDLINE DCOM- 20111012 LR - 20220330 IS - 1872-8294 (Electronic) IS - 0169-409X (Linking) VI - 63 IP - 3 DP - 2011 Mar 18 TI - Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. PG - 161-9 LID - 10.1016/j.addr.2010.09.003 [doi] AB - The success of an effective drug delivery system using liposomes for solid tumor targeting based on EPR effects is highly dependent on both size ranging from 100-200 nm in diameter and prolonged circulation half-life in the blood. A major development was the synthesis of PEG-liposomes with a prolonged circulation time in the blood. Active targeting of immunoliposomes to the solid tumor tissue can be achieved by the Fab' fragment which is better than whole IgG in terms of designing PEG-immunoliposomes with prolonged circulation. For intracellular targeting delivery to solid tumors based on EPR effects, transferrin-PEG-liposomes can stay in blood circulation for a long time and extravasate into the extravascular of tumor tissue by the EPR effect as PEG-liposomes. The extravasated transferrin-PEG-liposomes can maintain anti cancer drugs in interstitial space for a longer period, and deliver them into the cytoplasm of tumor cells via transferrin receptor-mediated endocytosis. Transferrin-PEG-liposomes improve the safety and efficacy of anti cancer drug by both passive targeting by prolonged circulation and active targeting by transferrin. CI - Copyright (c) 2010 Elsevier B.V. All rights reserved. FAU - Maruyama, Kazuo AU - Maruyama K AD - Faculty of Pharmaceutical Sciences, Teikyo University, Suarashi, Midori-ku, Sagamihara, Japan. maruyama@pharm.teikyo-u.ac.jp LA - eng PT - Journal Article PT - Review DEP - 20101028 PL - Netherlands TA - Adv Drug Deliv Rev JT - Advanced drug delivery reviews JID - 8710523 RN - 0 (Antineoplastic Agents) RN - 0 (Liposomes) SB - IM MH - Animals MH - Antineoplastic Agents/*administration & dosage/pharmacokinetics/therapeutic use MH - *Capillary Permeability MH - Drug Delivery Systems/*methods MH - Endocytosis/physiology MH - Extravasation of Diagnostic and Therapeutic Materials/metabolism/pathology/*physiopathology MH - Humans MH - Liposomes MH - Neoplasms/*blood supply/*drug therapy/metabolism/pathology/physiopathology EDAT- 2010/09/28 06:00 MHDA- 2011/10/13 06:00 CRDT- 2010/09/28 06:00 PHST- 2010/03/18 00:00 [received] PHST- 2010/07/31 00:00 [revised] PHST- 2010/09/01 00:00 [accepted] PHST- 2010/09/28 06:00 [entrez] PHST- 2010/09/28 06:00 [pubmed] PHST- 2011/10/13 06:00 [medline] AID - S0169-409X(10)00181-X [pii] AID - 10.1016/j.addr.2010.09.003 [doi] PST - ppublish SO - Adv Drug Deliv Rev. 2011 Mar 18;63(3):161-9. doi: 10.1016/j.addr.2010.09.003. Epub 2010 Oct 28.